{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:32Z","timestamp":1792806152337,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabres.2026.113474","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:05:05Z","timestamp":1785708305000},"page":"113474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Guideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes"],"prefix":"10.1016","volume":"239","author":[{"given":"Yingying","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-0869","authenticated-orcid":false,"given":"Seyed Adel","family":"Jahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Mong","family":"Bee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Pheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaicharn","family":"Deerochanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Pik","family":"Shan Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khue Thy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin Kumar","family":"Loganadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"McGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selva Elizabeth","family":"Trejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Y.Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.diabres.2026.113474_b0005","first-page":"S158","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","author":"Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1016\/j.diabres.2026.113474_b0010","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2026.113474_b0015","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113474_b0020","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2022;45(11):2753-86.","DOI":"10.2337\/dci22-0034"},{"issue":"3","key":"10.1016\/j.diabres.2026.113474_b0025","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s13300-018-0429-x","article-title":"Treatment intensification in type 2 diabetes: a real-world study of 2-OAD regimens, GLP-1 RAs, or basal insulin","volume":"9","author":"Blonde","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2026.113474_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110841","article-title":"Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: a retrospective database study (DEFINE-G)","volume":"203","author":"Ohsugi","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.diabres.2026.113474_b0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/ANNALS-24-03849","article-title":"Comparison of dose escalation versus switching to tirzepatide among people with type 2 diabetes inadequately controlled on lower doses of dulaglutide : a randomized clinical trial","volume":"178","author":"Billings","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2026.113474_b0040","unstructured":"Sch\u00fcnemann H BJ, Guyatt G, Oxman A 2013;Pageshttps:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html on Dec 30 2022."},{"key":"10.1016\/j.diabres.2026.113474_b0045","article-title":"The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines","volume":"352","author":"Brouwers","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113474_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.zefq.2017.10.008","article-title":"Ein instrument zur Erstellung von Leitlinienberichten: das RIGHT-statement","volume":"127\u20138","author":"Chen","year":"2017","journal-title":"ZEvid Fortbild Qual Gesundhwes"},{"issue":"3","key":"10.1016\/j.diabres.2026.113474_b0055","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s11606-019-05508-3","article-title":"A Comparison of AGREE and RIGHT: which clinical practice guideline reporting checklist should be followed by guideline developers?","volume":"35","author":"Yao","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"7","key":"10.1016\/j.diabres.2026.113474_b0060","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines international network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2026.113474_b0065","doi-asserted-by":"crossref","unstructured":"Alonso-Coello P, Sch\u00fcnemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. 2016;353:i2016.","DOI":"10.1136\/bmj.i2016"},{"key":"10.1016\/j.diabres.2026.113474_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111976","article-title":"GRADE notes 6: three strategies to determine the clinically important thresholds for outcomes in evidence-based guideline development","volume":"188","author":"Yao","year":"2025","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.diabres.2026.113474_b0075","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/1753-0407.13392","article-title":"Use of basal insulin in the management of adults with type 2 diabetes: an Asia-Pacific evidence-based clinical practice guideline","volume":"15","author":"Ji","year":"2023","journal-title":"J Diabetes"},{"issue":"5","key":"10.1016\/j.diabres.2026.113474_b0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/1753-0407.13381","article-title":"Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: a systematic review with meta-analysis","volume":"15","author":"Luo","year":"2023","journal-title":"J Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2026.113474_b0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13300-023-01493-3","article-title":"Comparison of effects of injectable semaglutide and dulaglutide on oxidative stress and glucose variability in patients with type 2 diabetes mellitus: a prospective preliminary study","volume":"15","author":"Omachi","year":"2024","journal-title":"Diabetes Ther"},{"issue":"3","key":"10.1016\/j.diabres.2026.113474_b0090","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jdi.12906","article-title":"Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial","volume":"10","author":"Takase","year":"2019","journal-title":"J Diabetes Investig"},{"issue":"11","key":"10.1016\/j.diabres.2026.113474_b0095","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.2337\/dc19-1357","article-title":"Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial","volume":"42","author":"Blonde","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2026.113474_b0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-016-0218-3","article-title":"The efficacy of IDegLira (insulin degludec\/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial","volume":"8","author":"Linjawi","year":"2017","journal-title":"Diabetes Ther"},{"issue":"7","key":"10.1016\/j.diabres.2026.113474_b0105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/dom.12661","article-title":"Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study)","volume":"18","author":"Aroda","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113474_b0110","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00125-024-06348-5","article-title":"Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial","volume":"68","author":"Lingvay","year":"2025","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.diabres.2026.113474_b0115","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jdiacomp.2013.04.008","article-title":"One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target","volume":"27","author":"Rosenstock","year":"2013","journal-title":"J Diabetes Complications"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:17:43Z","timestamp":1792804663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726003943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"alternative-id":["S0168822726003943"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113474","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113474"}}